News & Updates

Show Multimedia Only

CNS-penetrant oral RIPK1 inhibitor flops for ALS

The selective, oral, central nervous system-penetrant reversible RIPK1 inhibitor SAR443820 appears to have limited clinical benefit in amyotrophic lateral sclerosis (ALS) and is even associated with greater hepatic enzyme increase, according to the phase II HIMALAYA trial.

CNS-penetrant oral RIPK1 inhibitor flops for ALS

2 hours ago

Aficamten shows promise for nonobstructive HCM

6 hours ago by

Treatment with aficamten significantly improves patient-reported health status and exercise capacity in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), according to the ACACIA-HCM trial presented at ESC 2026.

Aficamten shows promise for nonobstructive HCM

6 hours ago

No link between tirzepatide and atrial fibrillation, arrhythmia

14 hours ago

Treatment with tirzepatide does not appear to be associated with atrial fibrillation or atrial arrhythmia in individuals with overweight or obesity, according to a meta-analysis.

No link between tirzepatide and atrial fibrillation, arrhythmia

14 hours ago

Two-drug noninferior to three-drug ART as initial HIV treatment

18 hours ago by

In individuals with untreated HIV-1 infection, the two-drug dolutegravir/lamivudine (DTG/3TC) antiretroviral therapy (ART) regimen has similar efficacy as the three-drug bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen, according to the phase IIIb VOGUE study.

Two-drug noninferior to three-drug ART as initial HIV treatment

18 hours ago

TSH testing patterns similar between GLP-1 RAs, SGLT-2 inhibitors in diabetes patients on levothyroxine

21 hours ago

Patterns of thyroid-stimulating hormone (TSH) test show no substantial difference between type 2 diabetes patients treated with GLP-1 RAs and those who received SGLT-2 inhibitors, a study has found.

TSH testing patterns similar between GLP-1 RAs, SGLT-2 inhibitors in diabetes patients on levothyroxine

21 hours ago

SUNRISE supports tezepelumab in severe OCS-dependent asthma

22 hours ago by

In the phase III SUNRISE trial, tezepelumab significantly reduces daily maintenance oral corticosteroid (OCS) dose while maintaining asthma control in adults with severe OCS-dependent asthma, despite early study termination and the smaller-than-planned sample size.

SUNRISE supports tezepelumab in severe OCS-dependent asthma

22 hours ago

Another oral OX2R agonist for narcolepsy type 1 clears phase II trial

a day ago

The novel oral orexin 2 receptor (OX2R) agonist alixorexton has demonstrated clinical benefits in patients with narcolepsy type 1, yielding improvements in wakefulness, excessive daytime sleepiness, and cataplexy, according to the phase II Vibrance-1 trial.

Another oral OX2R agonist for narcolepsy type 1 clears phase II trial

a day ago

Study: Avoid early 5-ASA treatment, adopt biologic-first approach in paediatric CD

a day ago by

Early treatment with 5-aminosalicylates (5-ASA) holds little benefit in children with newly diagnosed Crohn’s disease (CD), being associated with higher treatment failure rates, increased corticosteroid use, and reduced subsequent biologic therapy durability, according to a study.

Study: Avoid early 5-ASA treatment, adopt biologic-first approach in paediatric CD

a day ago

Pharmacist-led provider education improves antimicrobial discharge prescriptions

a day ago

A pharmacist-led provider education results in better prescribing patterns for antimicrobial discharge prescriptions, according to a study.

Pharmacist-led provider education improves antimicrobial discharge prescriptions

a day ago

Hormone therapy cuts CVD risk in women

23 Sep 2026

Initiation of hormone therapy during menopause or in recently postmenopausal women with vasomotor symptoms helps lower the risk of cardiovascular disease (CVD), according to a study.

Hormone therapy cuts CVD risk in women

23 Sep 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

CNS-penetrant oral RIPK1 inhibitor flops for ALS

CNS-penetrant oral RIPK1 inhibitor flops for ALS

Aficamten shows promise for nonobstructive HCM

Aficamten shows promise for nonobstructive HCM

No link between tirzepatide and atrial fibrillation, arrhythmia

No link between tirzepatide and atrial fibrillation, arrhythmia

Two-drug noninferior to three-drug ART as initial HIV treatment

Two-drug noninferior to three-drug ART as initial HIV treatment

TSH testing patterns similar between GLP-1 RAs, SGLT-2 inhibitors in diabetes patients on levothyroxine

TSH testing patterns similar between GLP-1 RAs, SGLT-2 inhibitors in diabetes patients on levothyroxine

SUNRISE supports tezepelumab in severe OCS-dependent asthma

SUNRISE supports tezepelumab in severe OCS-dependent asthma

Another oral OX2R agonist for narcolepsy type 1 clears phase II trial

Another oral OX2R agonist for narcolepsy type 1 clears phase II trial

Study: Avoid early 5-ASA treatment, adopt biologic-first approach in paediatric CD

Study: Avoid early 5-ASA treatment, adopt biologic-first approach in paediatric CD

Pharmacist-led provider education improves antimicrobial discharge prescriptions

Pharmacist-led provider education improves antimicrobial discharge prescriptions

Hormone therapy cuts CVD risk in women

Hormone therapy cuts CVD risk in women